{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:40:14Z","timestamp":1756305614796,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,27]]},"DOI":"10.7759\/cureus.91110","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:59:48Z","timestamp":1756303188000},"source":"Crossref","is-referenced-by-count":0,"title":["A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for Cytomegalovirus (CMV) Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol"],"prefix":"10.7759","author":[{"given":"Hannah","family":"Culpepper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Overstreet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylie","family":"Lively","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Scalea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McGillicuddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Taber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Overview: cytomegalovirus and the herpesviruses in transplantation","volume":"13","author":"Fishman JA","year":"2013","unstructured":"Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Ame Jr Trans. 2013, 13:1-8.","journal-title":"Ame Jr Trans"},{"key":"ref2","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan P","year":"2013","unstructured":"Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Inf Chem. 2013, 45:260.","journal-title":"Inf Chem"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13483","article-title":"Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence","volume":"23","author":"Raval AD","year":"2021","unstructured":"Raval AD, Kistler KD, Tang Y, et al.. Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence. Transpl Infect Dis. 2021, 23:e13483. 10.1111\/tid.13483","journal-title":"Transpl Infect Dis"},{"key":"ref4","article-title":"Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials","author":"Raval AD","year":"2020","unstructured":"Raval AD, Kistler K, Tang Y, et al.. Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials. Trans Rev. 2020,","journal-title":"Trans Rev"},{"key":"ref5","article-title":"Impact of cytomegalovirus disease in D+\/R-kidney transplant patients receiving 6 months low\u2010dose valganciclovir prophylaxis","volume":"11","author":"Luan FL","year":"2011","unstructured":"Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+\/R-kidney transplant patients receiving 6 months low\u2010dose valganciclovir prophylaxis. Amer Jr Trans. 2011, 11:1936-1942.","journal-title":"Amer Jr Trans"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/15269248211024614","article-title":"Predictors and complications of post kidney transplant leukopenia","volume":"31","author":"Vinson A","year":"2021","unstructured":"Vinson A, Teixeira A, Kiberd B, Tennankore K. Predictors and complications of post kidney transplant leukopenia. Prog Transplant. 2021, 31:249-56. 10.1177\/15269248211024614","journal-title":"Prog Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13617","article-title":"Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation","volume":"23","author":"Jorgenson MR","year":"2021","unstructured":"Jorgenson MR, Wong C, Descourouez JL, et al.. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation. Transpl Infect Dis. 2021, 23:e13617. 10.1111\/tid.13617","journal-title":"Transpl Infect Dis"},{"key":"ref8","article-title":"Efficacy and safety of ultra-low-dose valganciclovir chemoprophylaxis for cytomegalovirus infection in high-risk kidney transplantation patients","volume":"51","author":"Lee JH","year":"2019","unstructured":"Lee JH, Kim HY, Lee DY, et al.. Efficacy and safety of ultra-low-dose valganciclovir chemoprophylaxis for cytomegalovirus infection in high-risk kidney transplantation patients. Transplant Proc. 2019, 51:2689-2692.","journal-title":"Transplant Proc"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfx145","article-title":"High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation","volume":"11","author":"Rissling O","year":"2018","unstructured":"Rissling O, Naik M, Brakemeier S, et al.. High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation. Clin Kidney J. 2018, 11:564-573.","journal-title":"Clin Kidney J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1526924818765798","article-title":"Incidence and risk factors for leukopenia in kidney transplant recipients receiving valganciclovir for cytomegalovirus prophylaxis","volume":"28","author":"Liang X","year":"2018","unstructured":"Liang X, Famure O, Li Y, Kim SJ. Incidence and risk factors for leukopenia in kidney transplant recipients receiving valganciclovir for cytomegalovirus prophylaxis. Prog Transplant. 2018, 28:124-33. 10.1177\/1526924818765798","journal-title":"Prog Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13541","article-title":"Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation","volume":"33","author":"Hamel S","year":"2019","unstructured":"Hamel S, Kuo V, Sawinski D, et al.. Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clin Transplant. 2019, 33:e13541. 10.1111\/ctr.13541","journal-title":"Clin Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1526924817731880","article-title":"Evaluation of filgrastim therapy in kidney transplant recipients","volume":"27","author":"Poon T","year":"2017","unstructured":"Poon T, Guerra CM. Evaluation of filgrastim therapy in kidney transplant recipients. Prog Transplant. 2017, 27:360-4. 10.1177\/1526924817731880","journal-title":"Prog Transplant"},{"key":"ref13","article-title":"Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients","volume":"1","author":"Imlay HN","year":"2021","unstructured":"Imlay HN, Kaul DR. Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients. Clin Infect Dis. 2021, 1:156-160.","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens J","year":"2019","unstructured":"Maertens J, Cordonnier C, Jaksch P, et al.. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019, 381:1136-47. 10.1056\/NEJMoa1714656","journal-title":"N Engl J Med"},{"key":"ref15","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"8","author":"Papanicolaou GA","year":"2019","unstructured":"Papanicolaou GA, Silveira FP, Langston AA, et al.. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019, 8:1255-1264.","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston DJ","year":"2012","unstructured":"Winston DJ, Saliba F, Blumberg E, et al.. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012, 12:3021-30.","journal-title":"Am J Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70033-0","article-title":"Why did maribavir fail in stem-cell transplants?","volume":"11","author":"Snydman DR","year":"2011","unstructured":"Snydman DR. Why did maribavir fail in stem-cell transplants?. Lancet Infect Dis. 2011, 11:255-7. 10.1016\/S1473-3099(11)70033-0","journal-title":"Lancet Infect Dis"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty FM","year":"2011","unstructured":"Marty FM, Ljungman P, Papanicolaou GA, et al.. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011, 11:284-92.","journal-title":"Lancet Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery RK","year":"2010","unstructured":"Avery RK, Marty FM, Strasfeld L, et al.. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010, 12:489-96. 10.1111\/j.1399-3062.2010.00550.x","journal-title":"Transpl Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-6143.2005.00861.x","article-title":"MDRD equations for estimation of GFR in renal transplant recipients","volume":"5","author":"P\u00f6ge U","year":"2005","unstructured":"P\u00f6ge U, Gerhardt T, Palmedo H, et al.. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005, 5:1306-1311.","journal-title":"Am J Transplant"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2013.01.002","article-title":"Scientific registry of transplant recipients: Collecting, analyzing, and reporting data on transplantation in the United States","volume":"27","author":"Leppke S","year":"2013","unstructured":"Leppke S, Leighton T, Zaun D, et al.. Scientific registry of transplant recipients: Collecting, analyzing, and reporting data on transplantation in the United States. Transplant Rev. 2013, 27:50-56.","journal-title":"Transplant Rev"},{"key":"ref22","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","author":"Ljungman P","year":"2016","unstructured":"Ljungman P, Boeckh M, Hirsch HH, et al.. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Inf Dis. 2016,","journal-title":"Clin Inf Dis"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly RF","year":"2019","unstructured":"Chemaly RF, Chou S, Einsele H, et al.. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Inf Dis. 2019, 68:1420-1426.","journal-title":"Clin Inf Dis"},{"key":"ref24","article-title":"BK polyomavirus in solid organ transplantation","volume":"33","author":"Hirsch HH","year":"2019","unstructured":"Hirsch HH, Randhawa PS. BK polyomavirus in solid organ transplantation. Amr Jr Trans. 2019, 33:13528.","journal-title":"Amr Jr Trans"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16737","article-title":"Significant hospitalization cost savings to the payer with a pharmacist-led mobile health intervention to improve medication safety in kidney transplant recipients","volume":"21","author":"Taber DJ","year":"2021","unstructured":"Taber DJ, Fleming JN, Su Z, et al.. Significant hospitalization cost savings to the payer with a pharmacist-led mobile health intervention to improve medication safety in kidney transplant recipients. Am J Transplant. 2021, 21:3428-35. 10.1111\/ajt.16737","journal-title":"Am J Transplant"},{"key":"ref26","unstructured":"REDCap. Homepage. (2025). Accessed: August 26, 2025: https:\/\/project-redcap.org\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/334455-a-randomized-controlled-trial-comparing-the-tolerability-and-efficacy-of-maribavir-vs-valganciclovir-for-cytomegalovirus-cmv-prophylaxis-in-high-risk-kidney-transplant-recipients-study-protocol","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:59:51Z","timestamp":1756303191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/334455-a-randomized-controlled-trial-comparing-the-tolerability-and-efficacy-of-maribavir-vs-valganciclovir-for-cytomegalovirus-cmv-prophylaxis-in-high-risk-kidney-transplant-recipients-study-protocol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.91110","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}